About the work
Several studies have demonstrated that, on average, brain volume decreases by about 0.6-1% yearly in patients with MS. However, the pattern of atrophy is different in the different types of MS. Ventricular enlargement is predominant in RRMS involving the whole ventricular system. Cortical atrophy is more important in progressive forms (ventricular enlargement has reached a plateau); in SPMS some authors find a atrophy in the deep gray matter nuclei and in PPMS pericentral atrophy.
In CIS also exist subcortical changes in gray matter. Thalamic and central atrophy is associated with conversion to definite MS over 2 years. Therefore, measurement of thalamic atrophy is an ideal candidate for future clinical trials in CIS since it is useful for identifying patients at high risk of conversion to CDMS.
Despite a strong correlation to outcome, the measurement of thalamic atrophy (TA) is not being widely used in daily clinical practice as a criterion to predict outcome in MS. This is mainly because the volumetric methods available to date are sophisticated and difficult to implement for routine use in most hospitals. In addition, the results of complex volumetric studies are not always easy to understand so its practical value is not well-stablished yet.
Herein we propose a simple method to assess TA (and predict outcome in MS), based in the extent of thalamic atrophy in relation to the extent of global brain atrophy represented by ventricular enlargement. Although this method might be implemented using volumetry (3D), it can also be estimated using 2D-measures on one single MRI slide from 2 MRI studies performed at different times.
Print work information
Work information
Title The yearly rate of relative thalamic atrophy, a 2D/3D approach for assessing atrophy of the thalamus in daily clinical practice
Several studies have demonstrated that, on average, brain volume decreases by about 0.6-1% yearly in patients with MS. However, the pattern of atrophy is different in the different types of MS. Ventricular enlargement is predominant in RRMS involving the whole ventricular system. Cortical atrophy is more important in progressive forms (ventricular enlargement has reached a plateau); in SPMS some authors find a atrophy in the deep gray matter nuclei and in PPMS pericentral atrophy.
In CIS also exist subcortical changes in gray matter. Thalamic and central atrophy is associated with conversion to definite MS over 2 years. Therefore, measurement of thalamic atrophy is an ideal candidate for future clinical trials in CIS since it is useful for identifying patients at high risk of conversion to CDMS.
Despite a strong correlation to outcome, the measurement of thalamic atrophy (TA) is not being widely used in daily clinical practice as a criterion to predict outcome in MS. This is mainly because the volumetric methods available to date are sophisticated and difficult to implement for routine use in most hospitals. In addition, the results of complex volumetric studies are not always easy to understand so its practical value is not well-stablished yet.
Herein we propose a simple method to assess TA (and predict outcome in MS), based in the extent of thalamic atrophy in relation to the extent of global brain atrophy represented by ventricular enlargement. Although this method might be implemented using volumetry (3D), it can also be estimated using 2D-measures on one single MRI slide from 2 MRI studies performed at different times.
Work type Article
Tags alzheimer, neuroimaging, mtai, mild cognitive impairment, medial temporal lobe
-------------------------
Registry info in Safe Creative
Identifier 1311099180795
Entry date Nov 9, 2013, 3:53 PM UTC
License All rights reserved
-------------------------
Copyright registered declarations
Author. Holder Manuel Menendez Gonzalez. Date Nov 9, 2013.
Information available at https://www.safecreative.org/work/1311099180795-the-yearly-rate-of-relative-thalamic-atrophy-a-2d-3d-approach-for-assessing-atrophy-of-the-thalamus-in-daily-clinical-practice
/
Registration: 1311099180795
